AbbVie Lupin $977M+ Partnership to Develop Blood Cancer Inhibitors
--Sharing is Caring--

AbbVie Lupin $977M+ Partnership to Develop Blood Cancer Inhibitors

AbbVie will partner with Lupin, an Indian Biopharma company located in Mumbai, to develop and commercialize Lupin’s Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitors as novel therapies for various blood cancers, in a close to $1 billion collaboration.

Under the pact, Lupin has received exclusive international rights to Lupin’s MALT1 inhibitor program from AbbVie, dependent on the MALT1 protein included with T-cell and B-cell lymphocyte activation.

In this deal, Lupin received an upfront pay of $30 million from AbbVie for its exclusive license, and up to $947 million tied to attaining regulatory, development, and commercial landmarks. The deal also covers Lupin to get a double royalty on sales of treatments generated through the MALT1 inhibitor application in India.

“Lupin’s MALT1 program is researching a fresh and innovative approach in difficult-to-treat cancers,” Tom Hudson, M.D., AbbVie’s VP, discovery, said in a statement who was also a part of the Human Genome Project, linking the pioneering initiative for a postdoc in 1990 at MIT. He further added that AbbVie is committed to exploring innovative treatment choices for patients and the team looks forward to partner their expertise in hematological oncology with Lupin’s detection programme.

Nilesh Gupta, managing director, Lupin said that this association with AbbVie is a milestone deal as AbbVie is known for its commitment to deliver high-quality medicines in areas that lack proper medical need and therapies. This agreement perfectly couples with  AbbVie’s inclusion of oncology among its five therapeutic regions of attention.

See Also
Lab-Grown Meat Created Using Tissue Engineering

Lupin shares the same vision with AbbVie with Oncology being in their top three therapeutic ares of focus along with immunology and metabolic disorders under its Novel Drug Discovery and Development (NDDD) program.

Based on Lupin’s NDDD’s only clinical program in oncology has completed a Phase I study in Europe in terminally-ill patients with lung cancer, melanoma, and colon cancer–and has begun a Phase II research in India analyzing the treatment candidate’s efficacy in treating a parasite kind of lung cancer that has RAS mutations for which no therapy exists globally.

--Learning is Earning--

Learn New Techniques

Perfection is her hobby, Reliability is a synonym, Editing is her passion, Excellence is her Goal, Tactfulness is in her genes, Yellow is her Fav color. Preety Suman is the name of the Professional on whom entire BioTecNika relies when it comes to its website.A Gold Medalist in Biotech from SRM University, Chennai with a 9.9 CGPA ( was awarded the Gold Medal by Honorable Prime Minister of India Shri Narendra Modi , as seen in the pic ), She decided to join forces with BioTecNika to ensure India's largest BioSciences Portal expands its reach to every city in India.She has redesigned the new avatar of BioTecNika from scratch and heads the most dynamic, vibrant and well informed Online Team at Biotecnika Info Labs Pvt Ltd